Panhematin Market Report 2026

Panhematin Market Overview

• The Panhematin market growth in the historic period has been driven by limited treatment options for porphyria, orphan drug approvals • Market expansion is supported by improved rare disease diagnosis, expansion of acute porphyria awareness • Growth Driver: Increasing Diagnosis Of Genetic Disorders Driving The Growth Of The Panhematin Market • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Panhematin Market?

Panhematin is a hemin-based medication used primarily to treat acute porphyrias, a group of rare metabolic disorders affecting heme biosynthesis. It works by replenishing heme levels, which suppresses the production of porphyrin precursors that cause symptoms. The main types of panhematin are 350mg, 313mg. The 350mg dosage of Panhematin is used for treating acute porphyria episodes. The various indications include acute porphyria, and other indications. These are used in various applications such as hospitals, and pharmacies.

What Is The Panhematin Market Growth Forecast?

The panhematin market size is expected to see rapid growth in the next few years. It will grow to $4.24 million in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to improved rare disease diagnosis, expansion of acute porphyria awareness, increased access to orphan drugs, supportive reimbursement policies, growth of specialty care centers. Major trends in the forecast period include rising use in acute porphyria management, growth of orphan drug treatments, increased focus on rare metabolic disorders, expansion of hospital based emergency therapies, improved diagnostic awareness of porphyria.

What Are The Drivers Of The Panhematin Market?

The increasing diagnosis of genetic disorders is expected to propel the growth of the panhematin market going forward. Genetic disorders refer to medical conditions caused by abnormalities in an individual's genetic material, often requiring specialized treatments. The rise in diagnoses of genetic disorders is due to advancements in genetic testing and growing awareness, enabling early detection and timely intervention. Panhematin, a medication used in the treatment of acute porphyrias, helps genetic disorder patients by providing a synthetic form of heme, which aids in restoring the body's ability to regulate the production of porphyrins and heme, thus alleviating symptoms such as severe abdominal pain, nausea, and neurological complications that result from the accumulation of toxic porphyrins due to enzyme deficiencies in the heme biosynthesis pathway. For instance, in April 2023, a report published by the New England Journal of Medicine, a US-based medical journal, revealed that around 5,500 individuals with severe developmental disorders have now been identified with the genetic cause of their condition. Therefore, the increasing diagnosis of genetic disorders drives the Panhematin industry. Rising healthcare expenditure is expected to propel the growth of the panhematin market going forward. Healthcare expenditure refers to the financial resources allocated to health services, including diagnostics, treatments, and therapies, by governments, the private sector, and individuals. Rising healthcare expenditure is driven by factors such as an aging population, the prevalence of chronic diseases, advancements in medical technology, and increased demand for quality healthcare services. Healthcare expenditure for panhematin is primarily allocated toward treating acute porphyria attacks, covering costs for the drug, hospitalization, and associated care, ensuring effective management of this rare genetic disorder. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, rising healthcare expenditure drives the panhematin industry. The increasing cases of blood disorders are expected to propel the growth of the panhematin market going forward. Blood disorders are medical conditions that affect the production, function, or structure of blood cells, leading to issues such as anemia, clotting problems, or immune dysfunction. The increasing cases of blood disorders are primarily due to factors such as genetic predispositions, lifestyle changes, environmental influences, and the aging population. Panhematin, a form of heme arginate, helps blood disorder patients, particularly those with acute intermittent porphyria and other related conditions, by providing a synthesized heme molecule that bypasses the defective enzymes in the heme production pathway, thereby reducing the toxic buildup of porphyrins and alleviating symptoms such as pain, weakness, and neurological disturbances caused by these blood-related disorders. For instance, in May 2024, according to the National Health Service (NHS) England, a UK-based government-funded healthcare system, in England, approximately 17,000 people are living with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed annually. Therefore, the rising incidence of blood disorders drives the Panhematin industry.

Key Players In The Global Panhematin Market

Major companies operating in the panhematin market are Horizon Therapeutics plc.

What Defines the Panhematin Market?

The panhematin market consists of sales of intravenous (IV) formulations used to treat acute intermittent porphyria (AIP) and related heme synthesis disorders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Panhematin Market Report 2026?

The panhematin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the panhematin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.